Skip to content

FORMAPHARMA

Active
Private limited companyfounded 20251 yr activeRue de la Biche 5, 5300 Andenne, BelgiumKBO/BCE: BE 1022.806.404
Summary

FORMAPHARMA has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €14,461 and a net result of €12,461. Its solvency ranks better than 88% of 18458 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).

Checked score

Score 2025
Axes
Profitability100
Solvency100
Growth-
Track record67
Bankruptcy probability, 12 months
1.3% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €1,000 at 30 days acceptable
Liquidity ample (current ratio 5.69; short-term debt: 16.5% and cash: 63.9% of total assets), and 18.5% of the assets are financed with debt.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 1 year 0 10 y
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
81.5%
Return on assets
70.2%
Age of the figures
9 mo
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-07-2026, 7 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
7 d early
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

FORMAPHARMA was incorporated on 28 April 2025 as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Equity
€14,461
Total assets
€17,739
Net result
€12,461
Working capital
€13,705

Turnover and EBIT margin not published: the micro schema does not require them.

Balance-sheet composition
Equity and liabilities €17,739
Equity €14,461
Debt €3,278
Debt finances 18.5% of the balance-sheet total.
Key figures and ratios
2025 value
EBITDA
€16,029
Cash flow
€12,608
Current ratio
5.69
Debt to equity
0.23
ROE
86.2%
ROA
70.2%
Interest coverage
565.59
Debt ≤ 1 year
€2,921
Income taxes
€3,392

Peer companies

Historical observation

Of the 11,279 companies that looked in July 2024 the way this one looks now, 0.7% went bankrupt within 24 months and 97% are still going.

  • Micro
  • under 2 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
0.7% went bankrupt
2.6% stopped otherwise
97% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a higher bankruptcy probability: 1.3% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.6%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 11,279 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 31 lines
Balance sheet Code2025
Assets
Total assets20/58€17,739
Formation expenses20€1,112
Current assets29/58€16,627
Amounts receivable within one year40/41€5,214
Trade receivables40€4,606
Other amounts receivable41€608
Cash at bank and in hand54/58€11,341
Deferred charges and accrued income490/1€72
Equity and liabilities
Total equity and liabilities10/49€17,739
Equity10/15€14,461
Contributions10/11€2,000
Profit (loss) carried forward14€12,461
Amounts payable17/49€3,278
Amounts payable within one year42/48€2,921
Trade debts44€313
Suppliers440/4€313
Taxes, remuneration and social security45€1,915
Taxes450/3€1,915
Other amounts payable47/48€694
Accrued charges and deferred income492/3€357
Income statement Code2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€147
Other operating charges640/8€50
Gross operating margin9900€16,079
Operating profit (loss)9901€15,882
Financial charges65/66B€28
Recurring financial charges65€28
Profit (loss) for the period before taxes9903€15,853
Income taxes67/77€3,392
Profit (loss) for the period9904€12,461
Profit (loss) for the period to be appropriated9905€12,461
Appropriation of the result
Profit (loss) to be appropriated9906€12,461

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€147
Other operating charges640/8€50
Gross operating margin9900€16,079
Operating profit (loss)9901€15,882
Financial charges65/66B€28
Recurring financial charges65€28
Profit (loss) for the period before taxes9903€15,853
Income taxes67/77€3,392
Profit (loss) for the period9904€12,461
Profit (loss) for the period to be appropriated9905€12,461
Line2025
Assets
Total assets20/58€17,739
Formation expenses20€1,112
Current assets29/58€16,627
Amounts receivable within one year40/41€5,214
Trade receivables40€4,606
Other amounts receivable41€608
Cash at bank and in hand54/58€11,341
Deferred charges and accrued income490/1€72
Equity and liabilities
Total equity and liabilities10/49€17,739
Equity10/15€14,461
Contributions10/11€2,000
Profit (loss) carried forward14€12,461
Amounts payable17/49€3,278
Amounts payable within one year42/48€2,921
Trade debts44€313
Suppliers440/4€313
Taxes, remuneration and social security45€1,915
Taxes450/3€1,915
Other amounts payable47/48€694
Accrued charges and deferred income492/3€357
Line2025
Profit (loss) for the period9904€12,461
+ Depreciation and write-downs630€147
Operating cash flow (approximation)€12,608

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2026
24-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Andenne · 1 establishment unit since 2025
seat establishment The establishment unit on the map
Ground area
746 m²
Parcel 92081A0009/00C005, Wallonia. Linked by address, not a title deed.
1 establishment unit
Rue de la Biche 5, 5300 Andenne
Manufacture of basic pharmaceutical products and pharmaceutical preparations
since 20252.373.567.828
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
92081A0009/00C005 Wallonia 746 m² - -
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Recognitions · licences · registrations

Food safety, FASFC

1 site
Andenne2.373.567.828
2 permissions
Apotheek (LM>3 maand) · since 26-05-2025
Detailhandel LM>3 maand · since 26-05-2025

Similar companies · same sector, comparable size

Of 5,220 companies in sector 47730 we hold annual accounts for 3,860. 1,120 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded28-04-2025
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
70200Business and other management consultancy
86995Nutrition and dietetics services
Contact
E-mail hubert.emma@outlook.be
Phone +32479374990
E-invoicing
Reachable via Peppol
Peppol ID 0208:1022806404
Registered 28-12-2025

Register as of 26 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.